Board Meeting24 Jul 2026, 01:57 pm
Dr. Lal PathLabs Board Approves Interim Dividend, Stock Options, and Acquisitions
AI Summary
Dr. Lal PathLabs Ltd's Board of Directors met on July 24, 2026, approving un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were approved for eligible employees under the Restricted Stock Unit Plan 2025. The board also took note of acquisitions approved by its wholly-owned subsidiaries: Dr Lal PathLabs FZCO, Dubai, approved a stake acquisition in Sunshine Healthcare Limited (Ghana), and Dr. Lal Ventures Private Limited approved a stake acquisition in Neuome Technologies Private Limited.
Key Highlights
- Approved Q1 FY27 un-audited financial results.
- Declared interim dividend of ₹5 per share for FY27.
- Approved stock options grant to eligible employees.
- Noted subsidiary approvals for stake acquisitions in Ghana and India.
- Board meeting held on July 24, 2026.
Price Impact
More from LALPATHLAB